Trimetazidine is a clinically effective antianginal agent that has no negative inotropic or vasodilator properties. Although it is thought to have direct cytoprotective actions on the myocardium, the mechanism(s) by which this occurs is as yet undefined. In this study, we determined what effects trimetazidine has on both fatty acid and glucose metabolism in isolated working rat hearts and on th...

OBJECTIVE To study the in vitro transdermal permeation of trimetazidine from hydroxypropylmethyl cellulose (HPMC) gel drug reservoir system using nerodilol as a penetration enhancer. MATERIALS AND METHODS An HPMC gel containing selected concentrations of nerodilol (0, 2, 4 or 5% w/v) and 2.5% w/v of trimetazidine was prepared, and subjected to in vitro permeation studies across rat epidermis....

Trimetazidine, a clinically effective antianginal agent with no negative inotropic or vascular properties, acts by optimizing cardiac energy metabolism through inhibition of free fatty acid oxidation, shifting substrate utilization from fatty acids to glucose. Up to now there has been no study associating trimetazidine's effect on metabolic processes with glucose utilization in the mammalian br...

BACKGROUND Coronary artery bypass grafting (CABG) is a key and effective surgical treatment modality for coronary artery disease. Unfortunately, ischemia-reperfusion injury during and after CABG can lead to reversible and irreversible myocardial damage. Trimetazidine [1-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride] is a metabolic anti-ischemic agent with demonstrated cardioprotective effe...

The effects of trimetazidine, a novel anti-ischemic agent, on the development of oxidative stress induced in mice with lipopolysaccharide endotoxin were investigated. The drug was administered orally once daily at doses of 1.8, 3.6 or 7.2 mg/kg for two days prior to intraperitoneal (i.p.) injection of lipopolysaccharide E (200 μg/kg) and at time of endotoxin administration. Mice were euthanized...

The fraction of glucose passing through glycolysis that is oxidized is low in hypertrophied hearts, a pattern of glucose use associated with poor postischemic contractile function. We tested the hypothesis that trimetazidine, a partial 3-ketoacyl coenzyme A thiolase inhibitor, would stimulate glucose oxidation and, thereby, improve fractional glucose oxidation and postischemic function of hyper...

Objective To explore the protective effects of trimetazidine on vascular endothelial cells injury induced by hydrogen peroxide (H2O2) and its pharmacological mechanisms of anti-oxidation. Methods Human umbilical vein endothelial cells (HUVECs) were injured by H2O2. Next, the cells were treated with three different concentrations of trimetazidine (1μmol/L,10μmol/L,100μmol/L, respectively). The v...

BACKGROUND Exercise rehabilitation is demonstrated to improve the prognosis of patients with coronary heart disease (CHD). Statins, as the key medicine to lower cholesterol in CHD, result in skeletal muscle injury and impair exercise training adaptation. Energy metabolism dysfunction is identified as the potential mechanism underlying statin-induced skeletal muscle injury. In this study, we inv...

OBJECTIVE To evaluate the therapeutic effect of trimetazidine hydrochloride in peripheral vascular disease patients who had Rutherford classification grade 2-3. PATIENTS AND METHODS 72 patients with Rutherford classification grade 2-3 in peripheral vascular were recruited successfully, they were randomly assigned to control group (35 cases) and trimetazidine group (37 cases), patients in cont...

Early and successful myocardial reperfusion improves clinical outcomes of patients presenting with acute myocardial infarction (AMI). However, reperfusion itself can exacerbate myocardial injury beyond that caused by ischemia. The European Myocardial Infarction Project – Free Radicals trial (EMIP-FR) was one of the first studies that tested the hypothesis that a cardioprotective agent, such as ...